(Bloomberg) — The leading group of U.S. cancer doctors created a scoring system for oncology drugs, awarding a zero for overall benefit to the $9,200-a-month regimen featuring Eli Lilly & Co.'s Alimta.

The formula ranges from 0 to 100 points and was published Monday in the Journal of Clinical Oncology. It aims to simplify the complex statistics behind cancer medicines into a single "net health benefit" score that weighs a drug's ability to extend life or delay progression against potential toxic side effects.

The ultimate goal is to assess many drugs and put the data into a user-friendly mobile software application that patients and doctors can use at the bedside, said Richard Schilsky, chief medical officer for the American Society of Clinical Oncology, which convened a task force to assess value.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Broker Innovation Lab